The PMPRB (Patented Medicine Prices Review Board) has announced that they have further delayed the enforcement of the amended “Patented Medicines Regulations” to July 1, 2021. This is good news for all Canadians since the regulations which were revised to lower drug prices, have instead created barriers to new medicines for rare diseases.
The regulations as newly drafted and subsequently revised are not in line with what most stake-holders (including the vast majority of patient groups) wanted to see because the concerns raised during consultations have been largely ignored.
The announcement of the delay can be viewed here:
For a background on the process, we are providing the following online resources:
During the initial consultation in early 2020, aHUS Canada submitted a letter found HERE, and the Canadian Organization for Rare Disorders’ (C.O.R.D. -the national voice for the nearly 3 million Canadians affected by rare diseases) submission can be viewed HERE. C.O.R.D.’s submission to the amended regulations is HERE.
The complete list of submissions for the original draft of the new regulations:
The complete list of submissions for the amended regulations: